v3.26.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following table summarizes information for our single reportable segment, including significant segment expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue$24,397 $17,601 $67,170 $45,887 
Less:
Cost of sales3,933 3,008 10,778 7,680 
Early-stage research and development(1)
1,663 1,250 4,379 3,396 
Late-stage research and development(1)
2,584 2,216 7,197 6,140 
Marketing, selling, and administrative3,125 2,741 9,489 7,963 
Acquired in-process research and development4,181 656 7,541 2,381 
Other segment items(2)
2,460 2,148 6,844 4,325 
Net income$6,451 $5,583 $20,942 $14,002 
Interest expense$378 $180 $1,055 $672 
Expenditures for long-lived assets(3)
3,639 2,320 8,983 5,821 
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes.
(3) Includes expenditures for property and equipment and computer software costs.